A new editorial perspective titled “C/EBPβ cooperates with MYB to maintain the oncogenic program of AML cells” has been published in Oncotarget.
In this new paper, researcher Karl-Heinz Klempnauer from Westfälische-Wilhelms-Universität discusses recent studies on the role of transcription factor MYB in acute myeloid leukemia (AML). MYB has been identified as a key regulator of a transcriptional program for self-renewal of AML cells.
The MYB gene initially attracted attention as the progenitor of a retrovirally-transduced oncogene that induces a myeloid leukemia in chickens. MYB encodes a transcription factor with essential roles in the development of the hematopoietic system and the proliferation and differentiation of hematopoietic progenitor cells. Subsequent work identified MYB also as a crucial player in the development and maintenance of leukemia in humans.
“Recent work summarized here has now highlighted the CCAAT-box/enhancer binding protein beta (C/EBPβ) as an essential factor and potential therapeutic target that cooperates with MYB and coactivator p300 in the maintenance of the leukemic cells,” the paper states.
Karl-Heinz Klempnauer, C/EBPβ cooperates with MYB to maintain the oncogenic program of AML cells, Oncotarget (2023). DOI: 10.18632/oncotarget.28377
Impact Journals LLC
C/EBPβ cooperates with MYB to maintain the oncogenic program of AML cells (2023, November 13)
retrieved 13 November 2023
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.